Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs. Its revenue primarily comes from international markets, with Europe being a significant contributor. Financials show steady revenue and EBITDA growth over recent years. Investors with a high-risk appetite may consider this long-term opportunity.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.